Artemis Therapeutics Inc.
ATMSOTCFinancial Services
$0.50
$-1.39(-73.65%)
Market Cap$55792932
P/E Ratio—
52W High$4.5
52W Low$0.1121
Artemis Therapeutics Inc. (ATMS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATMS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.31M | $0.00M | $0.00M | $0.00M | $0.26M |
| Cost of Revenue | $0.05M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.26M | $0.00M | $0.00M | $0.00M | $0.26M |
| Gross Margin %(computed) | 82.64% | — | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.25M |
| G&A Expenses | $0.95M | $0.15M | $0.17M | $0.17M | $0.53M |
| Total Operating Expenses | $1.62M | $0.15M | $0.17M | $0.17M | $0.77M |
| Operating Income | ($1.36M) | ($0.15M) | ($0.17M) | ($0.17M) | ($0.77M) |
| Operating Margin %(computed) | -436.98% | — | — | — | -298.07% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.26M |
| Interest Expense | $0.00M | $0.01M | $0.01M | $0.01M | $0.00M |
| Income Before Tax | ($1.35M) | ($0.17M) | ($0.17M) | ($0.17M) | ($0.51M) |
| Income Tax Expense | ($0.00M) | $0.01M | ($0.05M) | ($0.05M) | $0.00M |
| Net Income | ($1.35M) | ($0.18M) | ($0.12M) | ($0.12M) | $0.51M |
| Net Margin %(computed) | -434.41% | — | — | — | 198.07% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.10 |
| Wtd Avg Shares | 57058.28M | 26.14M | 5.15M | 5.15M | 5.15M |
| EBITDA | ($1.34M) | ($0.15M) | ($0.17M) | ($0.17M) | ($0.51M) |
| EBITDA Margin %(computed) | -431.83% | — | — | — | -198.07% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Artemis Therapeutics Inc. data
About Artemis Therapeutics Inc. (ATMS) Income Statement
Artemis Therapeutics Inc. (ATMS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, ATMS reported revenue of $0.00B, gross profit of $0.00B (gross margin 82.64%), and net income of ($0.00B) — a net profit margin of -434.41%.
Frequently asked questions
ATMS · 4 questionsArtemis Therapeutics Inc. (ATMS) reported revenue of $0.00B for 2022, up —% year-over-year.
ATMS revenueATMS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09